Milrinone for the treatment of raised pressure in the lung vessels in neonates

Milrinone for the treatment of persistent pulmonary hypertension in term and late preterm infants - a pilot randomized controlled trial. - NeoMPH trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/11/021896

Enrollment

Registered

2019-11-06

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: P293- Persistent fetal circulation

Interventions

Intervention1: Milrinone: Patients will receive intravenous milrinone plus conventional therapy as per existing NICU protocol. Loading dose (50mcg/kg) followed by maintenance dose of 0.3 to 1 mcg/kg/m

Eligibility

Inclusion criteria

Inclusion criteria: 1.Infants of all gender with Gestational age >34 weeks and birth weight >=1800g 2. 3.Echocardiographic diagnosis of PPHN 4.Requirement for mechanical ventilation

Exclusion criteria

Exclusion criteria: 1.Major congenital anomalies or syndromes including congenital diaphragmatic hernia 2.Any congenital heart disease 3.Clinically evident bleeding diathesis or platelet count 4.Hypotension refractory to usual medical treatment (>=20 mL/kg fluid bolus and >=2 inotropes)

Design outcomes

Primary

Measure	Time frame
Duration of mechanical ventilationTimepoint: at discharge	—

Secondary

Measure	Time frame
Neonatal mortality Duration of oxygen therapy Duration of hospital stay Timepoint: 28 days at discharge at discharge	—

Countries

India

Contacts

Public ContactDr kGovindarajulu

JIPMER, Puducherry

plakkal@gmail.com7708577133

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026